(Q37235521)

19 August 2017

1 reference

title

Clinical management of drug addicts infected with human immunodeficiency virus and hepatitis C virus (English)

1 reference

19 August 2017

1 reference

1 reference

Jag H Khalsa

1

1 reference

19 August 2017

Frank Vocci

series ordinal

2

1 reference

19 August 2017

publication date

1 January 2008

1 reference

Journal of Addictive Diseases

19 August 2017

published in

1 reference

19 August 2017

volume

27

1 reference

19 August 2017

issue

2

1 reference

19 August 2017

page(s)

1-10

1 reference

Global impact of human immunodeficiency virus and AIDS.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Hepatitis C and HIV infections: implications for clinical care in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Low incidence and prevalence of hepatitis C virus infection among sexually active non-intravenous drug-using adults, San Francisco, 1997-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

HIV infection and cocaine use in methadone maintained and untreated intravenous drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Methadone maintenance treatment and HIV risk-taking behaviour among injecting drug users in Berlin

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

HIV post-exposure therapy for drug users in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Neurocognition in individuals co-infected with HIV and hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Medical care for injection-drug users with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Human immunodeficiency virus infection in intravenous drug users: a model for primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Effects of HIV triple therapy on methadone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Treating hepatitis C virus infection in active substance users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Hepatitis C virus infection and substance abuse: medical management and developing models of integrated care--an introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Hepatitis C virus infection in san francisco’s HIV-infected urban poor

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Detection of liver disease in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Current approaches to HCV infection in current and former injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Knowledge of and interest in hepatitis C treatment at a methadone clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Correlates of hepatitis C virus infections among injection drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Modelling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Epidemiology of hepatitis C virus infection in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Emotional stress, psychosocial variables and coping associated with hepatitis C virus and human immunodeficiency virus infections in intravenous drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Neuropsychiatric impact of hepatitis C on advanced HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Prevalence of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with co-occurring severe mental illness and substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Quality of life, symptomatology and healthcare utilization in HIV/HCV co-infected drug users in Miami

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Liver disease in injection drug users with hepatitis C, with and without HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Alcohol use and HIV pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Obstacles to successful HCV treatment in substance addicted patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

A golden opportunity: the treatment of hepatitis C in HIV-infected inmates

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Underlying Pathophysiology of HCV Infection in HIV-Positive Drug Users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_01

21 January 2018

Identifiers

DOI

10.1300/J069V27N02_01

1 reference

19 August 2017

1 reference